Export streamlining covers significant, nonsignificant risk devices with IDEs -- FDA proposal.
This article was originally published in The Gray Sheet
EXPORT OF INVESTIGATIONAL DEVICES WITHOUT FDA REVIEW will be allowed for both significant risk devices that have an approved investigational device exemption and nonsignificant risk products that do not require IDEs, the agency says in a proposed rule expected to be published in the Federal Register the week of Nov. 6. The proposal would allow devices that have approved IDEs to be exported to countries that say they will accept the products without FDA review.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.